PL2552959T3 - Przeciwciała przeciwko MUC16 i metody stosowania - Google Patents

Przeciwciała przeciwko MUC16 i metody stosowania

Info

Publication number
PL2552959T3
PL2552959T3 PL11760326T PL11760326T PL2552959T3 PL 2552959 T3 PL2552959 T3 PL 2552959T3 PL 11760326 T PL11760326 T PL 11760326T PL 11760326 T PL11760326 T PL 11760326T PL 2552959 T3 PL2552959 T3 PL 2552959T3
Authority
PL
Poland
Prior art keywords
methods
antibodies against
muc16
against muc16
antibodies
Prior art date
Application number
PL11760326T
Other languages
English (en)
Polish (pl)
Inventor
David Spriggs
Dharmarao Thapi
Original Assignee
Memorial Sloan-Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan-Kettering Cancer Center filed Critical Memorial Sloan-Kettering Cancer Center
Publication of PL2552959T3 publication Critical patent/PL2552959T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11760326T 2010-03-26 2011-03-25 Przeciwciała przeciwko MUC16 i metody stosowania PL2552959T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31796410P 2010-03-26 2010-03-26

Publications (1)

Publication Number Publication Date
PL2552959T3 true PL2552959T3 (pl) 2017-08-31

Family

ID=44673895

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11760326T PL2552959T3 (pl) 2010-03-26 2011-03-25 Przeciwciała przeciwko MUC16 i metody stosowania

Country Status (13)

Country Link
US (4) US9169328B2 (de)
EP (2) EP3222632A1 (de)
JP (8) JP5837567B2 (de)
AU (1) AU2011230590C1 (de)
CA (4) CA3002192C (de)
DK (1) DK2552959T3 (de)
ES (1) ES2621874T3 (de)
HK (1) HK1244496A1 (de)
HU (1) HUE032519T2 (de)
ME (1) ME02670B (de)
PL (1) PL2552959T3 (de)
PT (1) PT2552959T (de)
WO (1) WO2011119979A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02670B (de) 2010-03-26 2017-06-20 Memorial Sloan Kettering Cancer Center Antikörper gegen muc16 und anwendungsverfahren dafür
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
PL2961831T3 (pl) 2013-02-26 2020-12-14 Memorial Sloan Kettering Cancer Center Kompozycje i sposoby do immunoterapii
EP2971044B1 (de) * 2013-03-13 2018-05-09 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur behandlung von krebs
AU2015213437B2 (en) * 2014-02-07 2018-04-05 Mcmaster University Trifunctional T cell-antigen coupler and methods and uses thereof
AU2015218909A1 (en) * 2014-02-19 2016-08-04 Emergent Biosolutions Canada Inc. Marburg monoclonal antibodies
CN107106610A (zh) 2014-10-20 2017-08-29 朱诺治疗学股份有限公司 用于过继细胞治疗中的给药的组合物和方法
US9650428B2 (en) * 2014-12-02 2017-05-16 Roger Williams Hospital Methods and compositions for treating cancer
US11066480B2 (en) * 2015-03-17 2021-07-20 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof
CN107922488B (zh) * 2015-04-02 2021-08-27 纪念斯隆-凯特琳癌症中心 Tnfrsf14/hvem蛋白及其使用方法
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA42294B1 (fr) 2015-07-01 2020-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
EP3363814A4 (de) 2015-10-14 2019-09-25 Nippon Zenyaku Kogyo Co., Ltd. Anti-hund-tarc-antikörper zur behandlung und diagnose von atopischer dermatitis bei hunden
IL295398B2 (en) 2015-10-23 2025-01-01 Eureka Therapeutics Inc Antibody/T-cell receptor chimeric constructs and their uses
EP3494138A1 (de) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Zusammensetzungen und verfahren für tcr-programmierung mit fusionsproteinen
EP3515487B1 (de) * 2016-09-23 2023-07-19 Regeneron Pharmaceuticals, Inc. Bi spezifische anti-muc16-cd3-antikörper und anti-muc16-drogen-konjugate
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
WO2018098365A2 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018102795A2 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
EP3595668B1 (de) 2017-03-15 2021-07-21 Silverback Therapeutics, Inc. Benzazepinverbindungen, konjugate und verwendungen davon
AU2018256436B2 (en) 2017-04-19 2024-12-05 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
KR20250022233A (ko) 2017-04-26 2025-02-14 유레카 쎄라퓨틱스, 인코포레이티드 키메라 활성화 수용체 및 키메라 자극 수용체를 발현하는 세포 및 그의 용도
CN107557336B (zh) * 2017-09-15 2020-02-14 山东兴瑞生物科技有限公司 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用
CN111479925B (zh) 2017-10-12 2024-03-08 麦克马斯特大学 具有y182t突变的t细胞-抗原偶联物及其方法和用途
EP3755349A4 (de) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System Verfahren zur aktivierung und expansion von natürlichen killerzellen und deren verwendungen
RU2747095C2 (ru) * 2018-05-11 2021-04-26 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125
JP2021525534A (ja) * 2018-06-04 2021-09-27 プレシゲン，インコーポレイテッド Ｍｕｃ１６特異的キメラ抗原受容体およびそれらの使用
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US20210315933A1 (en) * 2018-07-26 2021-10-14 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using target specific fusion proteins
WO2020056192A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Antibody conjugates of toll-like receptor agonists
JP2022500414A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
AU2019337654A1 (en) 2018-09-12 2021-04-08 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
WO2020056194A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
WO2020085480A1 (ja) * 2018-10-26 2020-04-30 キッセイ薬品工業株式会社 高効率な遺伝子改変細胞の作製方法
US12168696B2 (en) * 2018-11-16 2024-12-17 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer
KR20210105890A (ko) 2018-12-17 2021-08-27 레비토프 리미티드 트윈 면역 세포 인게이저
JP7675016B2 (ja) * 2019-05-08 2025-05-12 メモリアル スローン ケタリング キャンサー センター ムチン－１６に対するヒト化抗体およびそれを使用する方法
WO2021019706A1 (ja) * 2019-07-31 2021-02-04 国立大学法人信州大学 Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
BR112022002720A2 (pt) 2019-08-15 2022-10-11 Silverback Therapeutics Inc Formulações de conjugados de benzazepinas e usos das mesmas
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN116209678A (zh) 2020-07-01 2023-06-02 安尔士制药公司 抗asgr1抗体缀合物及其用途
JP2023535371A (ja) 2020-07-17 2023-08-17 シミュレックス インコーポレイテッド 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法
EP4263600A1 (de) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimäre antigenrezeptorsysteme mit anpassbarer rezeptorspezifität
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
JP2024505075A (ja) 2021-01-29 2024-02-02 アロジーン セラピューティクス，インコーポレイテッド 同種細胞産物のＴ細胞認識を軽減するための、ＴＡＰ２、ＮＬＲＣ５、β２ｍ、ＴＲＡＣ、ＲＦＸ５、ＲＦＸＡＰ及びＲＦＸＡＮＫのうち１つ以上のノックダウン又はノックアウト
CA3173810A1 (en) 2021-06-01 2022-12-01 Andreas Bader Claudin 18.2 t cell-antigen couplers and uses thereof
AU2023312973A1 (en) 2022-07-29 2025-01-09 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN119978126A (zh) * 2023-11-10 2025-05-13 深圳市菲鹏生物治疗股份有限公司 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用
WO2025104253A1 (en) * 2023-11-17 2025-05-22 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025168802A1 (en) 2024-02-09 2025-08-14 Oslo Universitetssykehus Hf Chimeric antigen receptor binding to ca125 for treating ovarian cancer
CN119638843B (zh) * 2024-03-20 2025-08-26 武汉勖瑞生物科技有限责任公司 一种抗ca125蛋白的单克隆抗体及其应用
CN118791617B (zh) * 2024-07-02 2025-03-07 安徽德合功生物科技有限公司 Ca125单克隆抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US505713A (en) 1893-09-26 Thomas j
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
AU5554190A (en) 1989-05-08 1990-11-29 Mark I. Farber Process and apparatus for the recovery of precious metals from slag, tailings and other materials
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5976818A (en) * 1991-12-16 1999-11-02 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1995021381A1 (en) 1994-02-01 1995-08-10 The Rockefeller University Methods and agents for measuring and controlling multidrug resistance
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
ES2172149T3 (es) 1997-04-14 2002-09-16 Micromet Ag Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos.
CU22731A1 (es) 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2000077246A2 (en) 1999-06-14 2000-12-21 Novo Nordisk A/S A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DK1242401T3 (da) 1999-11-24 2007-05-07 Immunogen Inc Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
ITRM20010408A1 (it) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
US7202346B2 (en) * 2002-07-03 2007-04-10 Immunogen Inc. Antibodies to non-shed Muc1 and Muc16, and uses thereof
US6905839B2 (en) 2002-07-31 2005-06-14 Takashi Furuta In vivo phenotyping for human cytochrome P450 3A activity
GB2424070B (en) * 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
EP2289559B1 (de) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anti-CD70-Antikörper-Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs und Immunerkrankungen
EP1723178A4 (de) 2004-03-12 2007-12-12 Human Genome Sciences Inc Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10
CN1981054A (zh) 2004-05-14 2007-06-13 加利福尼亚大学董事会 用抗wnt2单克隆抗体和sirna治疗癌症的方法
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
SG155947A1 (en) * 2005-06-20 2009-10-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CA2683568A1 (en) * 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
ME02670B (de) 2010-03-26 2017-06-20 Memorial Sloan Kettering Cancer Center Antikörper gegen muc16 und anwendungsverfahren dafür
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method
WO2015006043A1 (en) 2013-07-09 2015-01-15 Board Of Regents Of The University Of Nebraska Novel method of targeting glycoproteins to treat cancer
US11066480B2 (en) 2015-03-17 2021-07-20 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof

Also Published As

Publication number Publication date
CA3188287C (en) 2025-07-08
CA3188287A1 (en) 2011-09-29
CA3002192A1 (en) 2011-09-29
EP3222632A1 (de) 2017-09-27
JP2018117634A (ja) 2018-08-02
CA2793753C (en) 2018-06-05
US11834513B2 (en) 2023-12-05
HUE032519T2 (en) 2017-09-28
JP2015025006A (ja) 2015-02-05
JP2024073610A (ja) 2024-05-29
WO2011119979A3 (en) 2012-04-05
US20130171152A1 (en) 2013-07-04
US10759869B2 (en) 2020-09-01
DK2552959T3 (en) 2017-05-01
JP7100595B2 (ja) 2022-07-13
AU2011230590B2 (en) 2015-01-15
JP2020072681A (ja) 2020-05-14
ES2621874T3 (es) 2017-07-05
WO2011119979A2 (en) 2011-09-29
JP2016144468A (ja) 2016-08-12
US20210309758A1 (en) 2021-10-07
ME02670B (de) 2017-06-20
PT2552959T (pt) 2017-04-21
US9790283B2 (en) 2017-10-17
JP2013529061A (ja) 2013-07-18
AU2011230590A2 (en) 2014-02-20
CA2793753A1 (en) 2011-09-29
EP2552959B1 (de) 2017-01-11
US20180230231A1 (en) 2018-08-16
JP6463068B2 (ja) 2019-01-30
HK1244496A1 (en) 2018-08-10
US20160168262A1 (en) 2016-06-16
CA3002192C (en) 2023-03-07
AU2011230590C1 (en) 2016-09-15
EP2552959A4 (de) 2013-08-14
JP2019116474A (ja) 2019-07-18
CA3255551A1 (en) 2025-04-15
US9169328B2 (en) 2015-10-27
JP5837567B2 (ja) 2015-12-24
AU2011230590A1 (en) 2012-10-11
EP2552959A2 (de) 2013-02-06
JP2022088649A (ja) 2022-06-14

Similar Documents

Publication Publication Date Title
PL2552959T3 (pl) Przeciwciała przeciwko MUC16 i metody stosowania
IL288070B (en) Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
IL280819A (en) Adeno-associated virus virions with variant capsid and methods of use thereof
IL244000A0 (en) Anti-fap antibodies and methods of use
ZA201304153B (en) Anti-pcsk9 antibodies and methods of use
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
PL2812443T3 (pl) Przeciwciała CD47 i sposoby ich zastosowania
PL3199024T3 (pl) Zastosowanie kompozycji cyklodekstryny i stosowne sposoby
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
BR112012017441A2 (pt) compostos e métodos
PL2427212T3 (pl) Przeciwciała anty cd-100 i sposoby ich zastosowania
BR112013014119A2 (pt) novos moduladores e métodos de uso
LT2605789T (lt) Modifikuoti relaksino polipeptidai ir jų panaudojimas
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
BR112014002716A2 (pt) anticorpos anti-poliubiquitina e métodos de uso
FI20105572A0 (fi) Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
HRP20181811T1 (hr) Zbirka sljedova protutijela i njezina upotreba
EP2734234A4 (de) Anti-cxcr4-antikörper und verwendungsverfahren dafür
HRP20181599T1 (hr) Proizvodnja i upotreba bakterijskog histamina
BR112014006291A2 (pt) composição e utilização da composição
IL231001B (en) Methods and compositions for producing capsicum plants with powdery mildew resistance
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
BR112014010774A2 (pt) anticorpos anti-kdr e métodos de uso
ME02992B (de) Agomelatin-zwischenprodukte und herstellungsverfahren dafür
BR112014000248A2 (pt) fago geneticamente modificado e uso deste